Kopran Limited , a prominent pharmaceutical company, is set to undergo a significant change in its shareholding structure as the promoter group prepares to acquire a 4.18% stake through an inter-family transfer. This move, scheduled for September 1, 2025, aims to resolve family disputes and streamline the company's ownership structure.

Key Details of the Transfer

The acquisition involves 20,15,985 equity shares, representing 4.18% of Kopran Limited's share capital. The transfer will be executed as a gift, without any monetary consideration, among family members. The key acquirers in this transaction include:

1. Varun Somani
2. Vadana Somani
3. Surendra Somani

These individuals will be joined by four associated entities acting in concert:

1. Oriental Enterprises Partnership Firm
2. Panaroma Finvest Private Ltd.
3. Parijat Shipping and Finale Limited
4. Sarvamangal Mercantile Company Ltd.

Transferors and Their Stakes

The shares will be transferred from eight family members, including:

Impact on Promoter Group Shareholding

This inter-family transfer will significantly impact the promoter group's stake in Kopran Limited:

• Before the transaction: The promoter group held 1,10,16,035 shares, representing 22.81% of the total share capital.
• After the transaction: The promoter group's holding will increase to 1,30,32,020 shares, accounting for 26.99% of the total share capital.

Rationale Behind the Transfer

The primary reasons for this inter-family transfer, as stated in the disclosure, are:

1. To resolve family disputes
2. To settle inequalities in the partition of the family business
3. To preserve family property by avoiding litigation
4. To maintain family honor

Regulatory Compliance

The transaction is exempt from open offer requirements under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically under Regulation 10(1)(a)(ii). The acquirers have declared that they will comply with all applicable disclosure requirements as per Chapter V of the SEBI Takeover Regulations.

Market Price Reference

For reference, the 60-day volume-weighted average market price of Kopran Limited's shares was:

• ₹178.65 on the Bombay Stock Exchange (BSE)
• ₹178.70 on the National Stock Exchange (NSE)

This inter-family share transfer marks a significant development for Kopran Limited, potentially leading to a more consolidated ownership structure within the promoter group. Shareholders and market observers will be keenly watching how this change might influence the company's future strategic decisions and performance.

Kopran Limited , a pharmaceutical company, has set September 4, 2025, as the record date for its upcoming dividend payment, subject to shareholder approval. The announcement comes as part of the company's preparations for its Annual General Meeting (AGM) scheduled for September 11, 2025.

Key Details

• Record Date: September 4, 2025
• AGM Date: September 11, 2025

Dividend Payment and Approval Process

The dividend payment is contingent upon approval by the company's shareholders at the upcoming AGM. If approved, the dividend will be subject to tax deduction at source, as per applicable regulations.

Regulatory Compliance

Kopran Limited has made this announcement in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) about the record date and AGM details.

Company Information

Kopran Limited is headquartered at Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. The company's manufacturing facilities are located in Village Savroli, Taluka Khalapur, District Raigad - 410 202.

Investors and shareholders are advised to take note of the record date for dividend eligibility. The final decision on the dividend declaration will be made at the Annual General Meeting, where members will have the opportunity to vote on the proposal.

Shareholders and potential investors are encouraged to attend or follow the proceedings of the Annual General Meeting on September 11, 2025, for the final decision on the dividend payment and other important company matters.